Comorbidities and polypharmacy impact on complete cytogenetic response in chronic myeloid leukaemia elderly patients

Alessandra Iurlo(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Agostino Cortelezzi(Istituti di Ricovero e Cura a Carattere Scientifico), Tommaso Radice(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Anna Ubertis(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Daniele Cattaneo(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Daniela Mari(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Silvia Artuso(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Manuela Zappa(Ospedale Maggiore), Cristina Bucelli(University of Milan)
European Journal of Internal Medicine
December 2, 2013
10.1016/j.ejim.2013.11.002
Cited by 34

Related Papers

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)
|Blood|2009|433
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial
|Journal of Clinical Oncology|2016|394
Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients
|Blood|2014|373
Angiogenesis in myelodysplastic syndromes
|British Journal of Cancer|1999|272
Hypercoagulability in centenarians: the paradox of successful aging
|Blood|1995|260